Clinical Trial Update: CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage [EARLY_Phase 1]

View source ↗

Summary

A pilot Phase 1 study at Rutgers is evaluating circulating tumor DNA as a biomarker in early-stage triple-negative and HER2-positive breast cancer. The trial is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Breast Cancer, Early-Onset | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING